All Oncology News

Internationally renowned surgeon and scientist Douglas A. Levine, MD, FACOG, FACS, whose seminal biomarker research has helped to advance early detection and treatment of ovarian cancer, will join the faculty of NYU Langone Medical Center as director of the Division of Gynecologic Oncology at its Laura and Isaac Perlmutter Cancer Center and the Department of Obstetrics and Gynecology.

The FDA has approved crizotinib as a treatment for patients with ROS1-positive metastatic non–small cell lung cancer.

OncLive and Holden Comprehensive Cancer Center at the University of Iowa have joined in a Strategic Alliance Partnership to promote public awareness of the latest advances in cancer research, diagnostics, and care.

Men with prostate cancer treated with radiotherapy were at higher risk for developing second malignancies in the bladder, colon, and rectum compared with men who were not exposed to radiotherapy.

The past decade of biomarker research has led to the introduction of several multigene prognostic tests that are now routinely used in clinical decision making to assist the se-lection of patients for adjuvant chemotherapy, and several other tests have emerged with potential clinical utility.

Jorge Garcia, MD, discusses CheckMate-025, the challenges with PD-1 as a biomarker, additional potential biomarkers, and why combination immunotherapy in renal cell carcinoma is still a work in progress.

Benjamin Levy, MD, discusses how nivolumab and pembrolizumab have impacted the treatment landscape of NSCLC, how to choose between the two for patients, and what biomarkers are in development for PD-1/PD-L1 agents.

The FDA has accepted a supplemental new drug application for pembrolizumab as a treatment for patients with advanced non–small cell lung cancer with PD-L1 expression on ≥1% of tumors cells.

Robert Andtbacka, MD, explains the goals of the retrospective analysis of the OPTiM study, the significance of its results, and the future for T-VEC in melanoma.

Treatment with rindopepimut (Rintega) plus temozolomide failed to improve overall survival compared with temozolomide and a control for patients with newly diagnosed EGFRvIII-positive glioblastoma multiforme.

The level of vitamin D in a patient’s blood could serve as a biomarker for an aggressive form of prostate cancer, especially in men who are considering active surveillance for the disease.

Michael Postow, MD, discusses the benefits and challenges of combination regimens versus single-agent regimens, the possibility of targeted agents with immunotherapies, and the management of toxicities with immunotherapies.

James L. Abbruzzese, MD, discusses the underlying disparity between high-volume centers and community medical centers affecting patients with pancreatic cancer.

Tomasz M. Beer, MD, FACP, discusses how having a deeper understanding of the genetic makeup of patients with castration-resistant prostate cancer would open the door to novel treatments, both monotherapy and combination regimens.

Michael Atkins, MD, discusses his views on the potential of immunotherapy versus targeted therapy in melanoma, what research has shown so far, and what could be on horizon for both classes of drugs going forward.

The FDA has approved ibrutinib (Imbruvica) for the frontline treatment of chronic lymphocytic leukemia based on data from the RESONATE-2 trial.

Selina Chen-Kiang, MD, discusses how CDK 4/6 inhibition sensitizes myeloma cells to IMiDs and the impact this can have on the treatment of patients with multiple myeloma.

A supplemental biologics license application has been submitted to the FDA to expand the approval of blinatumomab (Blincyto) to include the treatment of pediatric and adolescent patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Afatinib has received a positive opinion from the CHMP, recommending European approval for use in patients with advanced squamous cell non–small cell lung cancer following progression on platinum-based chemotherapy.

Chimeric antigen receptor-modified T-cell therapies continue to demonstrate promising signs of efficacy for patients with hematologic malignancies, including those with acute lymphoblastic leukemia and non-Hodgkin lymphoma.

Jason Luke, MD, discusses how molecular subtyping has expanded targeted therapy approaches beyond BRAF inhibition, current trials investigating emerging targeted agents, and what can be expected in this space going forward.

Craig Hofmeister, MD, discusses two clinical trials examining combination regimens in relapsed/refractory patients with multiple myeloma.

Jeffrey S. Weber, MD, PhD, discusses recent long-term follow-up data of dabrafenib and trametinib in melanoma that may shed some light on sequencing questions for BRAF-mutated patients.

Madhav Dhodapkar, MBBS, discusses research showing that nflammation and chronic stimulation of the immune system by lipids may trigger multiple myeloma in approximately one-third of all cases.

Second- or third-line treatment with tremelimumab monotherapy failed to improve overall survival compared with placebo for patients with unresectable malignant mesothelioma.

Sunil Verma, MD, discusses emerging key agents in the neoadjuvant setting, advantages of treating prior to surgery, and questions that still remain regarding HER2-positive neoadjuvant therapy.

OncLive, the acclaimed platform of resources for the practicing oncologist, is now streaming an insightful and provocative video editorial with pioneering oncologist and author Dr. Vincent T. DeVita Jr., who penned "The Death of Cancer: After Fifty Years on the Front Lines of Medicine, a Pioneering Oncologist Reveals Why the War on Cancer Is Winnable - and How We Can Get There."

Omid Hamid, MD, discusses promising agents and combinations that offer hope to patients with melanoma for whom standard checkpoint agents and/or targeted therapies are not an option.

The study calls for changes to reduce health disparities.

Yale Cancer Center researchers have identified a link between lipids and a third of all myelomas, a type of cancer affecting plasma cells.